Clearside Biomedical Inc (CLSD)
1.28
0.00 (0.00%)
USD |
NASDAQ |
May 08, 15:41
Clearside Biomedical Profit Margin (Quarterly): -76.15% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -76.15% |
| September 30, 2023 | -1.08K% |
| June 30, 2023 | -894.5% |
| March 31, 2023 | -232.0K% |
| December 31, 2022 | -2.93K% |
| September 30, 2022 | -2.94K% |
| June 30, 2022 | -2.03K% |
| March 31, 2022 | -2.20K% |
| December 31, 2021 | 72.83% |
| September 30, 2021 | -159.0% |
| June 30, 2021 | -781.4% |
| March 31, 2021 | -21.62K% |
| December 31, 2020 | -64.65K% |
| September 30, 2020 | -70.89% |
| June 30, 2020 | -1.63K% |
| March 31, 2020 | -71.05% |
| Date | Value |
|---|---|
| December 31, 2019 | -159.4% |
| September 30, 2019 | -4.64K% |
| June 30, 2019 | -12.74K% |
| March 31, 2019 | -34.23K% |
| December 31, 2018 | -72.13K% |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | -29.99K% |
| September 30, 2017 | -11.83K% |
| June 30, 2017 | -10.59K% |
| March 31, 2017 | -207.5K% |
| December 31, 2016 | -193.7K% |
| September 30, 2016 | -112.9K% |
| June 30, 2016 | -102.0K% |
| March 31, 2016 | -1.08K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-232.0K%
Minimum
Mar 2023
72.83%
Maximum
Dec 2021
-18.45K%
Average
-1.63K%
Median
Jun 2020
Profit Margin (Quarterly) Benchmarks
| Cassava Sciences Inc | -- |
| Heron Therapeutics Inc | -31.33% |
| Actinium Pharmaceuticals Inc | -- |
| Karyopharm Therapeutics Inc | -124.0% |
| Ocular Therapeutix Inc | -197.4% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -79.77% |
| Operating Margin (Quarterly) | -45.94% |
| Return on Net Operating Assets | -828.2% |